
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc. has demonstrated strong growth potential with its Pharmacogenomics segment, which experienced a 14% year-over-year increase in 2024, bolstered by a notable 23% growth in its GeneSight product. The company’s prenatal testing services, including Prequel and Foresight, achieved a combined growth rate of 12% in the fourth quarter of 2024 and 17% for the entire fiscal year, indicating robust demand and potential for re-acceleration moving forward. Additionally, Myriad is poised for future growth opportunities, particularly with an anticipated expansion of its hereditary cancer screening test in the second half of 2025, alongside favorable market dynamics in hereditary testing and potential legislative developments in biomarker legislation.
Bears say
Myriad Genetics has encountered significant challenges that contribute to a negative outlook, including the loss of reimbursement from a private payer for its GeneSight product and changes to NCCN guideline language, both of which are expected to impact near-term revenue negatively. Additionally, the firm has struggled to maintain and develop relationships with payors, which are crucial for its operational performance, leaving it vulnerable to further declines as competition and technological advancements intensify. The stock has plummeted over 50% in the past six months, compounded by risks related to price erosion, lower-than-expected volume growth, and a slowdown in the unaffected population business due to prolonged EMR workflow conversions.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares